?. Atg-hpxrhigh-fidelity, P. , ;. F. Hoffmann-la-roche-ltd, 5. , 5. et al., insertion into pIRESneo (BD Biosciences ? Clontech) digested with EcoRI/BamHI. Human CYP24 promoter deletions were obtained by PCR (Pfu polymerase ; Promega Corp.) using CYP24 forward 18-mer oligonucleotide primers (?1) with an overhanging SalI site immediately upstream of the 5?-most base of the deletion construct; a common 3? primer, TGCATTTATGGAGACAGA (CYP24 ?39 to ?22); and the human CYP24 (?1,250 to +99) pBLCAT3 plasmid as a template (a gift from PCR products were then digested by SacI and subcloned in SacI/SmaI?linearized pGL3basic vector (Promega Corp.) to produce ?1,200-LUC, ?326-LUC, and ?144-LUC constructs. pGL3tkLUC plasmid was obtained by ligation of the HindIII/BglII tk-SEAP vector fragment (BD Biosciences ? Clontech), corresponding to the minimal 147nt long tk promoter, into the HindIII/BglII?linearized pGL3basic vector. Oligonucleotides corresponding to the individual CYP2B6 NR1 (55), CYP24 site 3 (?316 to ?291), and VDREs (VDRE-II, ?294 to ?274, and VDRE-I, ?174 to ?151) (37) were synthesized with BamHI and BglII ends, annealed, and ligated, and 3 copies were subcloned into the BamHI/BglII?digested pGL3tk. The resulting (NR1)3-tkLUC, (site 3)3-tkLUC, (VDRE-II)3-tkLUC, and (VDRE-I)3-tkLUC were verified by sequencing. The specific mutations of the VDREs in the native CYP24 promoter (?326 to ?22) were introduced by PCR-based site-directed mutagenesis (QuikChange PCR-mediated site-directed mutagenesis kit; Stratagene) using ?326-LUC vector as a template to produce ?VDRE-I ( ?168 CCC mutated to GTT) and ?VDRE-II ( ?289 CACC mutated to AAAA). The ?VDRE-II vector was then used as a template to produce the ?VDRE-I + ?VDRE-II (?VDREs) construct. Primary culture of human hepatocytes. Hepatocytes were prepared from lobectomy segments resected from adult patients for medically required purposes unrelated to our research program. The use of these human hepatic specimens for scientific purposes has been approved by the French National Ethics Committee Hepatocytes were prepared and cultured according to a previously published procedure (56). The cells were plated into collagen-coated dishes at 0.17 × 10 6 cells per square centimeter in a hormonally and chemically defined medium consisting of a mixture of Williams's E medium and Ham's F12 medium (1:1 in volume) Forty-eight hours after plating, cells were cultured in the presence of the indicated concentrations of compounds Two microliters of diluted RT reaction (1:10) was used for real-time PCR amplification seconds seconds seconds), of cDNA encoding amino acids 1?434 of human PXR using oligonucleotides Quantitative PCR. Total RNA was extracted from cells or frozen mouse tissues using TRIZOL reagent (Invitrogen Corp.), according to the manufacturer's instructions. Purity was confirmed by spectrophotometry. cDNAs were synthesized from 1?2 ?g of total RNA using the SuperScript II first-strand synthesis system for PCR (Invitrogen Corp.) at 42°C for 60 minutes, in the presence of random hexamers (Amersham Pharmacia Biotech). Quantification of mRNAs was performed using the LightCycler apparatus The following program was used: a denaturation step at 95°C for 8 minutes, and 50 cycles of PCR all cases, the quality of the PCR product was assessed by monitoring of a fusion step at the end of the run, pp.5-5

J. B. Cheng, D. L. Motola, D. J. Mangelsdorf, R. , and D. W. , De-orphanization of Cytochrome P450 2R1: A MICROSOMAL VITAMIN D 25-HYDROXYLASE, Journal of Biological Chemistry, vol.278, issue.39, pp.38084-38093, 2003.
DOI : 10.1074/jbc.M307028200

K. Wikvall, Cytochrome P450 enzymes in the bioactivation of vitamin D to its hormonal form (Review), International Journal of Molecular Medicine, vol.7, pp.201-209, 2001.
DOI : 10.3892/ijmm.7.2.201

C. Carlberg, P. , and P. , Gene Regulation by Vitamin D3, Critical Reviews?? in Eukaryotic Gene Expression, vol.8, issue.1, pp.19-42, 1998.
DOI : 10.1615/CritRevEukarGeneExpr.v8.i1.20

S. Kato, The Function of Vitamin D Receptor in Vitamin D Action, Journal of Biochemistry, vol.127, issue.5, pp.717-722, 2000.
DOI : 10.1093/oxfordjournals.jbchem.a022662

C. Carlberg, The concept of multiple vitamin D signaling pathways, J. Investig. Dermatol. Symp. Proc, vol.1, pp.10-14, 1996.

A. S. Dusso and A. J. Brown, Mechanism of vitamin D action and its regulation, American Journal of Kidney Diseases, vol.32, issue.4, pp.13-24, 1998.
DOI : 10.1053/ajkd.1998.v32.pm9808140

L. Drocourt, J. C. Ourlin, J. M. Pascussi, P. Maurel, and M. J. Vilarem, Expression of CYP3A4, CYP2B6, and CYP2C9 Is Regulated by the Vitamin D Receptor Pathway in Primary Human Hepatocytes, Journal of Biological Chemistry, vol.277, issue.28, 2002.
DOI : 10.1074/jbc.M201323200

C. Segura, Vitamin D receptor ontogenesis in rat liver, Histochemistry and Cell Biology, vol.112, issue.2, pp.163-167, 1999.
DOI : 10.1007/s004180050403

T. Suda, T. Shinki, and K. Kurokawa, The mechanisms of regulation of vitamin D metabolism in kidney, Current Opinion in Nephrology and Hypertension, vol.3, issue.1, pp.59-64, 1994.
DOI : 10.1097/00041552-199401000-00008

Y. Ohyama, Identification of a vitamin D-responsive element in the 5?-flanking region of the rat 25-hydroxyvitamin D3 24-hydroxylase gene, 1994.

R. St-arnaud, Deficient Mineralization of Intramembranous Bone in Vitamin D-24-Hydroxylase-Ablated Mice Is Due to Elevated 1,25-Dihydroxyvitamin D and Not to the Absence of 24,25-Dihydroxyvitamin D, Endocrinology, vol.141, issue.7, pp.25-2658, 2000.
DOI : 10.1210/en.141.7.2658

D. L. Andress, Antiepileptic Drug???Induced Bone Loss in Young Male Patients Who Have Seizures, Archives of Neurology, vol.59, issue.5, pp.781-786, 2002.
DOI : 10.1001/archneur.59.5.781

R. Burt, J. W. Freston, and K. G. Tolman, The Influence of Phenobarbital on Biotransformation of 25-Hydroxycholecalciferol, The Journal of Clinical Pharmacology, vol.43, issue.8-9, pp.393-398, 1976.
DOI : 10.1002/j.1552-4604.1976.tb02413.x

Y. Karaaslan, S. Haznedaroglu, and M. Ozturk, Osteomalacia Associated with Carbamazepine/Valproate, Annals of Pharmacotherapy, vol.205, issue.2, pp.264-265, 2000.
DOI : 10.1038/clpt.1981.154

O. 'hare, J. A. Duggan, B. O-'driscoll, D. Callaghan, and N. , Biochemical evidence for osteomalacia with carbamazepine therapy, Acta Neurologica Scandinavica, vol.i, issue.5, pp.282-286, 1980.
DOI : 10.1111/j.1600-0404.1980.tb03037.x

S. C. Shah, R. K. Sharma, . Hemangini, and A. R. Chitle, Rifampicin induced osteomalacia, Tubercle, vol.62, issue.3, pp.207-209, 1981.
DOI : 10.1016/0041-3879(81)90008-8

M. J. Brodie, Rifampicin and vitamin D metabolism, Clinical Pharmacology and Therapeutics, vol.27, issue.6, pp.810-814, 1980.
DOI : 10.1038/clpt.1980.115

T. Y. Chan, Osteomalacia during rifampicin and isoniazid therapy is rare in Hong Kong, Int. J. Clin. Pharmacol. Ther, vol.34, pp.533-534, 1996.

M. J. Brodie, Effect of rifampicin and isoniazid on vitamin D metabolism, Clinical Pharmacology and Therapeutics, vol.32, issue.4, pp.525-530, 1982.
DOI : 10.1038/clpt.1982.197

J. C. Kolars, P. Schmiedlin-ren, J. D. Schuetz, C. Fang, and P. B. Watkins, Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes., Journal of Clinical Investigation, vol.90, issue.5, pp.1871-1878, 1992.
DOI : 10.1172/JCI116064

L. Pichard, Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem, Drug Metab. Dispos, vol.18, pp.711-719, 1990.

J. L. Raucy, Regulation of CYP3A4 Expression in Human Hepatocytes by Pharmaceuticals and Natural Products, Drug Metabolism and Disposition, vol.31, issue.5, pp.533-539, 2003.
DOI : 10.1124/dmd.31.5.533

L. Bertilsson, G. Tybring, J. Widen, M. Chang, and T. Tomson, Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19, British Journal of Clinical Pharmacology, vol.44, issue.2, pp.186-189, 1997.
DOI : 10.1046/j.1365-2125.1997.00630.x

J. M. Lehmann, The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions., Journal of Clinical Investigation, vol.102, issue.5, pp.1016-1023, 1998.
DOI : 10.1172/JCI3703

B. Goodwin, L. B. Moore, C. M. Stoltz, D. D. Mckee, and S. A. Kliewer, Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor, Mol. Pharmacol, vol.60, pp.427-431, 2001.

G. Luo, CYP3A4 Induction by Drugs: Correlation between a Pregnane X Receptor Reporter Gene Assay and CYP3A4 Expression in Human Hepatocytes, Drug Metabolism and Disposition, vol.30, issue.7, pp.795-804, 2002.
DOI : 10.1124/dmd.30.7.795

S. A. Kliewer, An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway, Cell, vol.92, issue.1, pp.73-82, 1998.
DOI : 10.1016/S0092-8674(00)80900-9

M. Makishima, Vitamin D Receptor As an Intestinal Bile Acid Sensor, Science, vol.296, issue.5571, pp.1313-1316, 2002.
DOI : 10.1126/science.1070477

J. M. Pascussi, S. Gerbal-chaloin, L. Drocourt, P. Maurel, and M. J. Vilarem, The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors, Biochimica et Biophysica Acta (BBA) - General Subjects, vol.1619, issue.3, pp.243-253, 2003.
DOI : 10.1016/S0304-4165(02)00483-X

A. Toell, K. D. Kroncke, H. Kleinert, and C. Carlberg, Orphan nuclear receptor binding site in the human inducible nitric oxide synthase promoter mediates responsiveness to steroid and xenobiotic ligands, Journal of Cellular Biochemistry, vol.98, issue.1, pp.72-82, 2002.
DOI : 10.1002/jcb.10104

P. Schmiedlin-ren, P. E. Thummel, J. M. Fisher, M. F. Paine, and P. B. Watkins, Induction of CYP3A4 by 1 alpha,25-dihydroxyvitamin D3 is human cell line-specific and is unlikely to involve pregnane X receptor, Drug Metab. Dispos, vol.29, pp.1446-1453, 2001.

K. E. Thummel, Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3, Mol. Pharmacol, vol.60, pp.1399-1406, 2001.

C. Theodoropoulos, C. Demers, E. Delvin, D. Menard, and M. Gascon-barre, Calcitriol regulates the expression of the genes encoding the three key vitamin D3 hydroxylases and the drug-metabolizing enzyme CYP3A4 in the human fetal intestine, Clinical Endocrinology, vol.239, issue.4, pp.489-499, 2003.
DOI : 10.1210/jc.86.2.888

K. S. Chen and H. F. Deluca, Cloning of the human 1??,25-dihydroxyvitamin D-3 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements, Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression, vol.1263, issue.1, pp.1-9, 1995.
DOI : 10.1016/0167-4781(95)00060-T

K. D. Wagner, N. Wagner, V. P. Sukhatme, and H. Scholz, Activation of vitamin D receptor by the Wilms' tumor gene product mediates apoptosis of renal cells, J. Am. Soc. Nephrol, vol.12, pp.1188-1196, 2001.

A. Zou, M. G. Elgort, A. , and E. A. , Retinoid X Receptor (RXR) Ligands Activate the Human 25-Hydroxyvitamin D3-24-hydroxylase Promoter via RXR Heterodimer Binding to Two Vitamin D-responsive Elements and Elicit Additive Effects with 1,25-Dihydroxyvitamin D3, Journal of Biological Chemistry, vol.272, issue.30, pp.19027-19034, 1997.
DOI : 10.1074/jbc.272.30.19027

J. Roy-chowdhury, J. Locker, R. , and N. , Nuclear Receptors Orchestrate Detoxification Pathways, Developmental Cell, vol.4, issue.5, pp.607-608, 2003.
DOI : 10.1016/S1534-5807(03)00131-X

URL : http://doi.org/10.1016/s1534-5807(03)00131-x

S. A. Kliewer, The nuclear pregnane X receptor regulates xenobiotic detoxification, J. Nutr, vol.133, pp.2444-2447, 2003.

I. Dussault, Peptide Mimetic HIV Protease Inhibitors Are Ligands for the Orphan Receptor SXR, Journal of Biological Chemistry, vol.276, issue.36, pp.33309-33312, 2001.
DOI : 10.1074/jbc.C100375200

W. Xie and R. M. Evans, Pharmaceutical use of mouse models humanized for the xenobiotic receptor, Drug Discovery Today, vol.7, issue.9, pp.509-515, 2002.
DOI : 10.1016/S1359-6446(02)02251-1

J. L. Staudinger, The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity, Proceedings of the National Academy of Sciences, vol.8, issue.2, pp.3369-3374, 2001.
DOI : 10.1016/S0168-8278(96)80268-6

J. L. Omdahl, E. A. Bobrovnikova, S. Choe, P. P. Dwivedi, M. et al., Overview of regulatory cytochrome P450 enzymes of the vitamin D pathway, Steroids, vol.66, issue.3-5, pp.381-389, 2001.
DOI : 10.1016/S0039-128X(00)00157-4

N. Akeno, A. Matsunuma, T. Maeda, T. Kawane, and N. Horiuchi, Regulation of vitamin D-1alpha-hydroxylase and -24-hydroxylase expression by dexamethasone in mouse kidney, Journal of Endocrinology, vol.164, issue.3, pp.339-348, 2000.
DOI : 10.1677/joe.0.1640339

S. Chung and C. Ahn, Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children, Brain and Development, vol.16, issue.5, pp.382-385, 1994.
DOI : 10.1016/0387-7604(94)90125-2

D. Erasmo, E. Ragno, A. Raejntroph, N. Pisani, and D. , Drug-induced osteomalacia, Recenti Prog. Med, vol.89, pp.529-533, 1998.

U. H. Munch, G. Lupi, and H. J. Kistler, Osteomalacia and antiepileptic drugs: study on the pathogenesis, Schweiz. Med. Wochenschr, vol.105, pp.608-615, 1975.

S. Tomita, J. Ohnishi, M. Nakano, and Y. Ichikawa, The effects of anticonvulsant drugs on vitamin D3-activating cytochrome P-450-linked monooxygenase systems, The Journal of Steroid Biochemistry and Molecular Biology, vol.39, issue.4, pp.479-485, 1991.
DOI : 10.1016/0960-0760(91)90241-V

M. J. Glesby, Bone Disorders in Human Immunodeficiency Virus Infection, Clinical Infectious Diseases, vol.37, issue.s2, pp.91-95, 2003.
DOI : 10.1086/375884

K. Mondy and P. Tebas, Emerging Bone Problems in Patients Infected with Human Immunodeficiency Virus, Clinical Infectious Diseases, vol.36, issue.s2, pp.101-105, 2003.
DOI : 10.1086/367566

P. Tebas, Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy, AIDS, vol.14, issue.4, pp.63-67, 2000.
DOI : 10.1097/00002030-200003100-00005

J. Fernandez-rivera, Relationship Between Low Bone Mineral Density and Highly Active Antiretroviral Therapy Including Protease Inhibitors in HIV-Infected Patients, HIV Clinical Trials, vol.74, issue.1, pp.337-346, 2003.
DOI : 10.1007/s00223-001-1048-4

J. T. Moore and S. A. Kliewer, Use of the nuclear receptor PXR to predict drug interactions, Toxicology, vol.153, issue.1-3, pp.1-10, 2000.
DOI : 10.1016/S0300-483X(00)00300-0

T. Sueyoshi, T. Kawamoto, I. Zelko, P. Honkakoski, and M. Negishi, The Repressed Nuclear Receptor CAR Responds to Phenobarbital in Activating the Human CYP2B6 Gene, Journal of Biological Chemistry, vol.274, issue.10, pp.6043-6046, 1999.
DOI : 10.1074/jbc.274.10.6043

L. Pichard, Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes, Mol. Pharmacol, vol.41, pp.1047-1055, 1992.

F. Zeghoud, A. Jardel, H. Guillozo, T. M. Nguyen, and M. Garabedian, Micromethod for the determination of 25-hydroxyvitamin D. In Vitamin D: gene regulation, structure-function analysis, and clinical application, Proceedings of the Eighth Workshop on Vitamin D, pp.662-663, 1991.

M. A. Preece, J. H. O-'riordan, D. E. Lawson, and E. Kodicek, A competitive protein-binding assay for 25-hydroxy-cholecalciferol and 25-hydroxyergocalciferol in serum, Clinica Chimica Acta, vol.54, issue.2, pp.235-242, 1974.
DOI : 10.1016/0009-8981(74)90241-1